UnitedHealth spent most of the last decade being the stock nobody argued with. It compounded through recessions, through a pandemic, through two changes in Washington’s mood about managed care, and the chart just kept climbing. Then 2025 happened. Operating margin fell from 8.1 percent to 4.2 percent in a single fiscal year, a decline of nearly half, and the stock has spent the months since trying to figure out whether that was a one-time gash or the new normal. I don’t think the market has decided yet, and neither have I, but I’ve come around to a specific way of framing the question that I think is more useful than the headlines.
The Number That Actually Matters
Forget the DOJ headlines for a second, forget the CEO change, forget the reinstated forecast that got pulled and reissued lower. The single number that tells you what happened to UnitedHealth in 2025 is the medical care ratio, the share of premium revenue that gets paid straight back out in claims. When that ratio moves against an insurer, everything else in the income statement follows it down, because premiums are priced a year in advance based on a cost forecast, and if the forecast is wrong the insurer eats the difference for that whole cycle before it can reprice.
UnitedHealth underpriced its 2025 book. Utilization in Medicare Advantage ran hotter than the actuaries assumed, coding intensity reviews compressed what the company could bill for risk adjustment, and the Optum side of the business, which usually cushions insurance-arm volatility, got hit by the same cost trend from the provider side. The financials tab shows the mechanics plainly: revenue kept growing, roughly flat to up low single digits, while operating income cratered. That combination, growing top line and collapsing operating leverage, is the signature of a pricing miss, not a demand problem.
UnitedHealth isn’t the first managed-care name to get caught by this exact mechanism. Humana and Centene both went through their own versions of a Medicare Advantage utilization surprise in 2023 and 2024, underpricing a book against a cost trend that ran hotter than the actuarial models assumed, and both saw sharp single-year margin compression followed by a repricing cycle that took one to two years to fully restore profitability. Neither fully recovered its old margin band on the first attempt, the initial repricing usually undershoots the actual cost trend and requires a second correction the following year, which is a pattern worth keeping in mind before assuming a single repriced book fixes everything at once.
The chart is the whole argument in one picture. This wasn’t a gradual fade. Margin held in an 8 to 9 percent band for four straight years and then fell off a cliff in the fifth. Insurers reprice their books every January, so the mechanical question for 2026 is whether the 2026 premium book was priced with the 2025 cost trend baked in, or whether management is still catching up. Every earnings call from here is going to be an argument about which one is true, and I don’t think you can know for certain until at least two quarters of the new pricing cycle have printed.
Why the Balance Sheet Buys Time
What keeps me from writing this off as a broken business is that UnitedHealth is not fighting for its life while it fixes pricing. This is a company with a market capitalization near $345 billion and a P/E ratio, even after the margin collapse, of about 24.7 times trailing earnings, per the valuation tab. That is not a distressed multiple. It is roughly in line with the broader market, which tells you the market has already priced in a meaningful recovery, not a further leg down. Compare that to where a broken insurer trades, typically under 10 times earnings with a dividend under threat, and UnitedHealth is nowhere near that zone.
The dividend, currently yielding about 2.33 percent, has not been cut, and the payout ratio even at depressed 2025 earnings is not screaming for one. Scale is also a real moat here in a way it wasn’t for, say, a regional insurer caught in the same cost trend: UnitedHealth’s size gives Optum’s pharmacy and provider-services arms negotiating leverage that smaller peers don’t have, and that leverage doesn’t evaporate because one year’s actuarial assumptions were wrong.
| Metric | Value | Read |
|---|---|---|
| Operating margin, FY2025 | 4.2% | down from 8.1% a year earlier |
| P/E (TTM) | 24.7x | close to the broader market, not distressed |
| Dividend yield | 2.33% | uncut, payout not stretched |
| StockVane Quant Rating | C · 38 | mid-pack, not a fresh buy signal |
| Wall Street consensus | Buy · 80% buy-rated | average target near $488, well above spot |
That last row is the interesting tension. Wall Street’s analyst consensus is far more optimistic than the stock’s current momentum profile, with an average price target that implies real upside from here and four out of five covering analysts still at buy. The StockVane Quant Rating, which leans on trailing price momentum rather than analyst sentiment, sits at a middling C, which is really just the model saying the stock hasn’t proven anything yet on the tape. Those two views aren’t contradictory so much as they’re measuring different things: one is a bet on the fundamentals repairing, the other is a read on whether the market has started believing it yet.
This Has Happened Before, Just Not at This Scale
Managed-care insurers mis-pricing a cost cycle is not a new phenomenon. Humana went through a version of this in 2023 and 2024 as Medicare Advantage utilization ran hot industry-wide, and its stock took a comparable percentage hit to its multiple before stabilizing once the repriced book started showing through in the numbers. If you want the mechanics of how a cost-trend miss actually flows through an income statement, this earlier piece on reading an earnings report walks through the operating-leverage math in more general terms. The pattern in insurance mispricing specifically, and in most episodes I’ve looked at, is that the correction happens in two steps: a sharp margin hit in the mispriced year, followed by an overcorrection in the next repricing cycle that restores margin faster than a straight-line recovery would suggest, because actuaries who just got burned tend to price conservatively for a few years afterward. If UnitedHealth follows that pattern, 2026 margin should land somewhere between the 2025 trough and the old 8 percent band, with a fuller recovery by 2027.
The difference this time is scale and duration of scrutiny. Humana’s episode was framed almost entirely as a utilization story. UnitedHealth’s has a Department of Justice inquiry layered on top of it, plus a CEO transition, plus a temporarily pulled and reissued guidance, all in the same twelve-month window. Any one of those on its own is a manageable headline. Stacked together, they’re the reason the stock’s momentum score is so much weaker than its valuation would otherwise suggest, the market isn’t pricing pure utilization risk anymore, it’s pricing headline risk, and headline risk resolves on a much less predictable timeline than an actuarial cycle does.
The Two Numbers I’m Watching
I want to be specific here rather than hand-wavy, because “wait for margins to recover” is not a falsifiable forecast. The thing I’m watching is the medical care ratio in the first two quarters of the repriced book, reported against the guidance management gives alongside it. If the ratio comes in at or below guidance for two consecutive quarters, that’s evidence the actuaries caught up to the cost trend, and the stock is meaningfully undervalued at a market multiple for a franchise that should, once repriced, earn back toward its old margin band over a few years. If the ratio keeps surprising to the high side, the market multiple stops looking reasonable and starts looking like it’s still catching up to a worse reality.
The other thing worth tracking, separate from the numbers, is the regulatory overhang. A Department of Justice inquiry into Medicare Advantage billing practices doesn’t need to end in a guilty finding to cost the company money and management attention for years; investigations of this scale rarely resolve quickly, and the uncertainty itself acts as a multiple suppressant even if the eventual outcome is manageable. I don’t model a specific fine into my numbers because I have no reliable way to size one, but I do treat it as a reason the stock should trade at some discount to a “clean” version of itself until there’s more clarity, which is roughly consistent with where it sits today relative to the market.
My own read, for whatever it’s worth: I think the size of the margin collapse overshot the size of the actual pricing miss, because managed-care repricing tends to overcorrect in the year after a bad surprise, insurers get conservative on purpose. That would argue for some margin recovery in 2026 even before you assume the underlying cost trend itself moderates. But I’m not treating this as a name to chase into strength. The setup I’d actually act on is a confirmed two-quarter improvement in the medical care ratio joined to a stock that’s still trading near a market multiple, because that’s the version of this story where the fundamentals move first and the price hasn’t caught up. Buying the story before the ratio confirms it is a bet on management’s word over a track record that just failed once, and I’d rather not make that bet with size.
Gavin Thorne writes on equity strategy and company-level research. This article reflects his personal research process and is intended for informational purposes only. It does not constitute investment advice.